JDRF Applauds Congress for Passage of $300 Million for Type 1 Diabetes Research and Thanks Supporters for Advocacy Efforts for Special Diabetes Program Renewal

This press release is an announcement submitted by JDRF, and was not written by Diabetes Health.

A Statement from JDRF President and CEO, Jeffrey Brewer

Dec 13, 2010

"Congress passed a multi-year renewal of the Special Diabetes Program (SDP), ensuring that studies on promising diabetes treatments and avenues toward a cure continue uninterrupted. As the father of a son living with type 1 diabetes, and as CEO of JDRF, one of the leading advocates for the renewal of this program, I applaud the U.S. government for its continued commitment to end this disease.

At a time when the incidence of diabetes, both type 1 and 2, is rising and when a CDC modeling study predicts that one in three Americans will be living with diabetes by the year 2050, our nation cannot afford to falter in its support for research that will help to lessen and ultimately eliminate the burden of diabetes from our healthcare system.

We have made progress toward better treatments. We have also made progress toward a cure.  But we're not there yet. Advancing science takes time, and breakthroughs are unpredictable. We at JDRF are trying to accelerate the process by identifying and filling gaps to help bring products to patients as quickly and safely as possible by providing significant funding and direction to type 1 diabetes research. But we can't do it alone. And this is why we are excited to see the U.S. government renew its commitment to diabetes research today. The combination of federal diabetes research funding and private investments through JDRF has created one of the most effective public-private partnerships focused on disease research.

The SDP is unique because it supplements annually-appropriated NIH-research funding with a mandatory funding stream for type 1 diabetes research. Currently, the SDP represents 35 percent of all the federal research on type 1 diabetes. Since its establishment in 1997, the program has produced tangible scientific and clinical results, and real returns on the federal investment in type 1 diabetes research.

An example of an advance, funded both by the SDP and JDRF, was announced earlier this year when results from a clinical trial conducted by The National Eye Institute of the National Institutes of Health (NIH) and the Diabetic Retinopathy Clinical Research Network (DRCR.net) showed that a drug (known as Lucentis), when combined with the current standard treatment of laser therapy, is more effective than the current medical treatment in treating diabetic eye disease for people with type 1 and type 2 diabetes. The pivotal data showed that after one year, nearly half of the patients in the trial treated with drug and laser therapy improved their vision by at least two lines on a standard eye chart, concluding that the drug when combined with the current standard treatment of laser therapy, improved vision significantly. This is really good news for those with diabetes and for the productivity of our workforce as a whole, as diabetic eye disease is the most common cause of visual loss in working age Americans.

Also, both the SDP and JDRF have provided significant support for the development of an artificial pancreas - a closed-loop system that will enable a person with diabetes to maintain normal glucose levels by providing the right amount of insulin at the right time, just as the pancreas does in individuals without diabetes. Tests have been conducted successfully in a hospital environment. The next step is for these devices to be tested in outpatient settings.

Congress' action today marks the fifth time the SDP has been renewed, committing $150 million annually for the two years of the program. Its renewal will allow us to continue and build on the program's advances to date by translating those discoveries into treatments and eventually cures for people with diabetes.

Thanks to the strong, ongoing bipartisan support of Congress, the SDP is making a real difference. We also thank the Members of Congress who have championed this program and recognize the importance of accelerating research efforts to find a cure for type 1 diabetes. And, a special thanks to our volunteers who have shared their stories about the toll that diabetes has on their families, and encouraged their Members of Congress to take action.  

Together we can help to improve the lives of those living with type 1 diabetes and eventually eliminate the disease once and for all."






Click Here To View Or Post Comments

Categories: Adolescent Boys, Adolescent Girls, Artificial Pancreas, Diabetes, Diabetes, Government & Policy, Health Care, Insulin, Kids & Teens, The Cure, Type 1 Issues, Type 2 Issues

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (2)

You May Also Be Interested In...


Posted by Anonymous on 15 December 2010

That is not exactly true,when W. became president he ended the program to grow new stem cells;only those already harvested were available for research after he vetoed it. Once they were used up the program stopped. Unless someone else knows different? But that was my understanding.

Posted by rodinsc on 26 May 2011

I am not sure I really understand why the JDRF is spending money on treatments like the closed loop artificial pancreas.

In my opinion, the JDRF should be spending all their money on a cure. Leave the spending for developing treatments to commercial companies. After all, it is a very lucrative business and companies can easily afford this spending.

Not to pick on any single manufacturer of diabetic supplies but let me illustrate this point with some numbers for Eli Lilly.

Last year, Ely Lilly had revenues of $23 billion dollars and earnings of $5 billion. They have $6 billion in cash. They have a profit margin of around 20%. It is a very profitable business and they will spend their own money to stay in it because treatments are very profitable. And this is just 1 company.

On the other hand, a cure for diabetes would not be a profitable business because there are no repeat sales to the same customer. So the diabetic supply manufacturers will not spend money on a cure, only treatments.

Non-profits like the JDRF are the only entities that can spend on a cure because they have no revenue stream to protect.

Please spend money on a cure - not treatments.

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.